Overview


According to FutureWise analysis, the market for generic injectables in 2023 is US$ 107.4 billion, and is expected to reach US$ 262.52 billion by 2031 at a CAGR of 11.82%.

The rising frequency of chronic illnesses has resulted in investments in generic injectables innovation. The increased popularity of intravenous (IV) or intramascular (IM) medication delivery techniques has stemmed from the desire for quick therapeutic choices. Generic injectables are also becoming more widely acknowledged as less expensive therapies when compared to branded counterparts. These considerations are driving increased generic injectable market acceptance rates. During the peak of the coronavirus outbreak in India's second wave, there was an extraordinary demand for Remdesivir, an antiviral medicine used to treat patients. Due to Remdesivir's scarcity, firms in the generic injectables market, such as Hetero Medications, an Indian pharmaceutical company and one of the world's leading producers of anti-retroviral drugs, launched Covifor, a generic version of Remdesivir.

Syringes are among the most difficult to examine containers. With the world's largest immunisation campaign in history, the issues posed by syringe inspection become increasingly pertinent when considering the increasing use of injectable medications. These results have resulted in the necessity for advanced inspection techniques to assist producers in dealing with not just the coronavirus pandemic but also a variety of other ailments. While other containers, such as cartridges, vials, and ampoules, can enter the inspection process independently, syringes are normally transported by conveyor and then flipped upside down. As a result, strong inspection methods are required so that any concealed particles in the funnel can sink down into the liquid, increasing inspection detectability.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Generic Injectables Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Generic Injectables Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Pfizer Inc.
  • Novartis AG (Sandoz International GmbH)
  • Baxter
  • Fresenius SECo. KGaA
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Hikma Pharmaceuticals PLC.
  • Lupin Ltd.
  • Sanofi
  • Biocon

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Large Molecule Injectables
    • mAb
    • Insulin
    • Others
  • Small Molecule Injectables

By Container Type

  • Vials
  • Ampoules
  • Premix
  • Prefilled syringes
  • Others

By Application

  • Oncology
  • Infectious diseases
  • Cardiology
  • Diabetes
  • Immunology
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

The Asia Pacific region is anticipated to lead the market during the forecast period owing to the increased demand of these injectables with the rising incidences of infectious diseases like typhoid, diarrhoea, cholera, malaria and cancers, high insistence for cheaper medical alternatives and a strong presence of key market players in the region. The North America region, on the other hand, is anticipated to proliferate the market during the forecasted timeframe owing to the approval of novel generic injectables and increasing insistence for cheaper biosimilar products along with increased occurrence of lifestyle-oriented diseases.


  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Generic Injectables Market By Product Type, By Container Type, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Generic Injectables Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Generic Injectables Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Generic Injectables Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Generic Injectables Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Large Molecule Injectables:
         1.1. mAb
         1.2. Insulin
         1.3. Others
        2. Small Molecule Injectables

  • 8.   Generic Injectables Market, By Container Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Vials
        2. Ampoules
        3. Premix
        4. Prefilled syringes
        5. Others

  • 9.   Generic Injectables Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology
        2. Infectious diseases
        3. Cardiology
        4. Diabetes
        5. Immunology
        6. Others

  • 10.   North America Generic Injectables Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Generic Injectables Market Analysis 2017-2022 and Forecast 2023-2031(USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Generic Injectables Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Generic Injectables Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •    1. Pfizer Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Novartis AG (Sandoz International GmbH)
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Baxter
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Fresenius SECo. KGaA
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Mylan N.V.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Teva Pharmaceutical Industries Ltd.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Hikma Pharmaceuticals PLC.
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Lupin Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Sanofi
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Biocon
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by Baxterinistrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients